Pomegra
Airway Therapeutics raised $50 million in a Series E equity round in August 2026, funding the Phase 2b/3 clinical trial of zelpultide alfa for preventing a life-threatening lung disease in very premature infants.
- Key Takeaways
- Airway Therapeutics closed a $50M Series E round on Aug. 25, 2026, combining $26M in SAFE notes with a $24M Series E-2.
- Cincinnati Children's Hospital and a group of family offices focused on respiratory disease anchored the round.
- An interim analysis of the Phase 2b portion is expected by end of Q2 2027, a key de-risking event for the program.
Lead
Airway Therapeutics, a Cincinnati-based biopharmaceutical company, closed a $50 million equity round on August 25, 2026 to fund its most advanced clinical program. The capital will sustain the Phase 2b arm of a combined Phase 2b/3 trial testing zelpultide alfa in infants born between 23 and 28 weeks of gestation - a population at exceptionally high risk of developing bronchopulmonary dysplasia (BPD), the most common serious respiratory disease in extremely premature newborns.
What Is Zelpultide Alfa, and Why Does It Matter?
Zelpultide alfa is a recombinant form of surfactant protein D (SP-D), a protein produced naturally in healthy lungs that suppresses inflammation and modulates immune responses in the airway. In very preterm infants, whose lungs have not fully developed, SP-D is functionally absent at birth. Mechanical ventilation - necessary to keep these infants alive - compounds the damage, causing the chronic lung injury that defines BPD. Zelpultide alfa is delivered intratracheally during ventilation, targeting the mechanism of injury at the moment it occurs.
The drug carries orphan designation in both the United States and the European Union, and the European Medicines Agency's Pediatric Committee has approved zelpultide alfa's study plan for BPD. The Phase 1b trial, which enrolled infants and completed dose escalation, established safety and tolerability up to 6 mg/kg over the first seven days of life - clearing the path to the ongoing pivotal study.
Why This Round, and What Does Its Structure Signal?
The $50 million is a hybrid raise: $26 million came from a SAFE financing already completed, with an additional $24 million from a new Series E-2 closing. Approximately 94% of existing investors participated in the E-2 portion - an unusually high re-up rate that reflects insider conviction rather than fresh outside enthusiasm. That matters for a company still three or more years from a regulatory filing.
Cincinnati Children's Hospital - where much of Airway's scientific collaboration is rooted - joined a syndicate of large family offices with thematic focus on respiratory medicine. No valuation was disclosed. The absence of a crossover institutional investor or a named biotech-specialist fund as anchor is notable; the round reads more like bridge capital to a key data readout than a pre-IPO growth raise.
The proceeds will also cover chemistry, manufacturing, and controls work and analytical activities necessary to support a future regulatory submission. These CMC costs tend to be underestimated in early-stage biotech rounds and Airway's decision to fund them in parallel with clinical work is operationally disciplined.
What Happens Next for the Trial?
The multinational Phase 2b/3 study - enrolling 316 infants across sites initially opened in Italy and Spain, with further geographic expansion underway - is structured to allow an interim analysis of the Phase 2b cohort by the end of Q2 2027. That readout will serve as the primary near-term catalyst. A positive signal would unlock the Phase 3 portion and likely trigger a significantly larger financing, probably with different investor types.
BPD affects roughly 30% of infants born before 32 weeks and close to half of those born before 28 weeks. As neonatal intensive care has extended survival to gestations as early as 22-23 weeks, the incidence of BPD has risen in parallel. The market for BPD therapies is projected to reach $472 million globally by 2035, though the patient population is small and concentrated in tertiary NICUs - meaning pricing would need to be substantial to sustain a commercial business.
Disease Context
No FDA-approved therapy currently exists specifically for preventing BPD. Standard of care involves caffeine, corticosteroids, and optimized ventilation strategies - none of which address the underlying inflammatory biology that zelpultide alfa is designed to interrupt. The lack of approved prevention options has made the indication attractive for orphan-drug developers despite the operational complexity of running trials in critically ill neonates.
Other programs in the space have historically struggled with endpoint definitions and enrollment rate, both of which the FDA and EMA have scrutinized closely. Airway's decision to run a single combined Phase 2b/3 adaptive trial - rather than sequential phases - compresses the timeline but concentrates risk at the interim readout.
Outlook
The Q2 2027 interim analysis will define the program's trajectory. A clear efficacy signal would position Airway for a substantially larger institutional raise and potentially attract a pharmaceutical partner for commercialization. A null or inconclusive result would require a reassessment of dose, endpoint, or enrollment criteria - and another financing at terms that would be more difficult to negotiate. The 94% re-up from existing investors buys time, but not indefinitely. The next twelve months are the program's real test.
